title: Influence of obesity on localized prostate cancer patients treated with radical prostatectomy.
abstract: This study aimed to investigate the association between different anthropometric measures of obesity and clinicopathological characteristics in Chinese patients with clinically localized prostate cancer (PCa). A total of 734 patients with clinically localized PCa who underwent radical prostatectomy (RP) were included in this study. Clinical and pathological data from each patient were collected. Anthropometric measures of abdominal adiposity were measured from T2-weighted sagittal localisation images from magnetic resonance imaging (MRI) for 413 (56.3%) patients. Patient clinical and pathological characteristics were compared across body mass index (BMI) groups. Univariable and multivariable logistic regression models were used to address the influence of the preoperative total testosterone level and anthropometric measures of obesity on pathological outcomes. In the multivariate analysis, BMI was not significantly associated with any pathological outcomes. However, the percentage of visceral adipose tissue (VAT%) was an independent predictor of a pathological Gleason score ≥8 (P<0.001), extracapsular extension (ECE; P=0.002) and seminal vesicle invasion (SVI; P=0.007). More importantly, we found that the preoperative total testosterone level was significantly correlated with the VAT% (Pearson's correlation coefficient: -0.485, P<0.001) and subcutaneous adipose tissue (SAT; Pearson's correlation coefficient: 0.413, P<0.001). In conclusion, the results of this study suggest that abdominal fat distribution, and particularly VAT%, is associated with a risk of advanced PCa. Moreover, our present study confirms a significant inverse correlation between visceral adiposity and testosterone. Further studies are warranted to elucidate the biological mechanisms underlying the relationship between abdominal adiposity and the aggressiveness of PCa.
authors.affiliation: 1] Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China [2] Department of Oncology, Fudan University Shanghai Medical College, Shanghai 200032, China.
authors.forename: Yuan-Yuan
authors.initials: YY
authors.lastname: Qu
authors.forename: Bo
authors.initials: B
authors.lastname: Dai
authors.forename: Yun-Yi
authors.initials: YY
authors.lastname: Kong
authors.forename: Kun
authors.initials: K
authors.lastname: Chang
authors.forename: Ding-Wei
authors.initials: DW
authors.lastname: Ye
authors.forename: Xu-Dong
authors.initials: XD
authors.lastname: Yao
authors.forename: Shi-Lin
authors.initials: SL
authors.lastname: Zhang
authors.forename: Hai-Liang
authors.initials: HL
authors.lastname: Zhang
authors.forename: Wei-Yi
authors.initials: WY
authors.lastname: Yang
mesh_terms: D000368:Aged; D015992:Body Mass Index; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications*; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000150:complications / Q000601:surgery*
references.citation: BJU Int. 2013 Jun;111(7):1031-6
references.pmid: 22883053
references.citation: Eur Urol. 2009 Jan;55(1):121-30
references.pmid: 18762364
references.citation: Urology. 2001 Nov;58(5):723-8
references.pmid: 11711349
references.citation: NCHS Data Brief. 2012 Jan;(82):1-8
references.pmid: 22617494
references.citation: Urology. 2009 Mar;73(3):615-9
references.pmid: 19010520
references.citation: Asian J Androl. 2008 Nov;10(6):923-8
references.pmid: 18958356
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):844-53
references.pmid: 21467239
references.citation: J Urol. 2013 Feb;189(2):447-53
references.pmid: 23253956
references.citation: N Engl J Med. 2003 Apr 24;348(17):1625-38
references.pmid: 12711737
references.citation: J Urol. 2007 Jan;177(1):102-6; discussion 106
references.pmid: 17162013
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3252-61
references.pmid: 18990768
references.citation: J Gastrointest Surg. 2013 Jan;17(1):133-43; discussion p.143
references.pmid: 23090279
references.citation: BJU Int. 2009 Apr;103(7):877-82
references.pmid: 19007372
references.citation: Int J Urol. 2009 Aug;16(8):676-81
references.pmid: 19602006
references.citation: World J Urol. 2008 Feb;26(1):91-5
references.pmid: 17940773
references.citation: Urology. 2012 Sep;80(3):576-84
references.pmid: 22925233
references.citation: J Endourol. 2008 Jul;22(7):1471-6
references.pmid: 18613784
references.citation: Urol Oncol. 2012 Sep;30(5):590-5
references.pmid: 21396843
references.citation: Urology. 2008 Nov;72(5):1106-10
references.pmid: 18602142
references.citation: Clin Endocrinol (Oxf). 2006 Jul;65(1):125-31
references.pmid: 16817831
references.citation: Cancer Causes Control. 2011 Aug;22(8):1141-51
references.pmid: 21678033
references.citation: Epidemiol Rev. 2007;29:88-97
references.pmid: 17478439
references.citation: Obes Res. 2004 Dec;12(12):1930-5
references.pmid: 15687393
references.citation: Clin Oncol (R Coll Radiol). 2010 May;22(4):281-8
references.pmid: 20189371
references.citation: Eur Urol. 2007 Aug;52(2):331-43
references.pmid: 17507151
references.citation: Prostate. 1995 Jan;26(1):40-9
references.pmid: 7531326
references.citation: Nat Rev Urol. 2011 Aug 02;8(9):483-94
references.pmid: 21811224
references.citation: BJU Int. 2012 Dec;110(11 Pt B):E667-72
references.pmid: 22974446
references.citation: Am J Epidemiol. 2006 Oct 15;164(8):769-74
references.pmid: 16952929